These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 19075046)

  • 1. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 2. [New antitubercular drugs].
    Krasucka-Kluźniak A
    Pneumonol Pol; 1990; 58(4-5):163-6. PubMed ID: 2168041
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicine. New TB drug promises shorter, simpler treatment.
    Cohen J
    Science; 2004 Dec; 306(5703):1872. PubMed ID: 15591168
    [No Abstract]   [Full Text] [Related]  

  • 4. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 5. Microbiology. TB--a new target, a new drug.
    Cole ST; Alzari PM
    Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for development of new antimycobacterial drugs.
    Tomioka H
    J Infect Chemother; 2000 Mar; 6(1):8-20. PubMed ID: 11810525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for new antitubercular drugs.
    Duncan K; Barry CE
    Curr Opin Microbiol; 2004 Oct; 7(5):460-5. PubMed ID: 15451500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.
    Sarathy J; Dartois V; Dick T; Gengenbacher M
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1648-53. PubMed ID: 23335744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones.
    Yew WW; Chan E; Chan CY; Cheng AF
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):936-7. PubMed ID: 12365583
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins.
    Mitchison DA
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1186-9. PubMed ID: 22794180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 14. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.
    Ananthan S; Faaleolea ER; Goldman RC; Hobrath JV; Kwong CD; Laughon BE; Maddry JA; Mehta A; Rasmussen L; Reynolds RC; Secrist JA; Shindo N; Showe DN; Sosa MI; Suling WJ; White EL
    Tuberculosis (Edinb); 2009 Sep; 89(5):334-53. PubMed ID: 19758845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular and genetic characterization of rifampicin- and/or izoniazid-resistent strains of M. tuberculosis, isolated in Novosibirsk and Tomsk regions].
    Tat'kov SI; Norkina OV; Filipenko ML; Sivkov AIu; Boldyrev AN; Azaev MSh; Kinsht VN; Kurunov IuN; Krasnov VA; Medvedeva EV; Baranova OI; Ivlev-Duntau AP; Bodnev SA; Blinova LN; Pasechnikov AD
    Vestn Ross Akad Med Nauk; 2005; (7):26-36. PubMed ID: 16107019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
    Tomioka H
    Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Zhang YJ; Li XJ; Mi KX
    Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis drug development: progress, challenges, and the road ahead.
    Ginsberg AM
    Tuberculosis (Edinb); 2010 May; 90(3):162-7. PubMed ID: 20382086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.